Table 2. Risk of the primary outcome (cardiovascular death, MI, stroke or admission for CHF) on Ramipril and Telmisartan, comparing Asians and Non-Asians in the ONTARGET Study.

	Overall	Asian	Non-Asian	p-value†
Ramipril	1412 (16.46%)	190 (16.07%)	1221 (16.52%)	0.775
Telmisartan	1423 (16.66%)	171 (14.59%)	1252 (16.99%)	0.082
HR (95% CI)*	1.01 (0.94–1.09)	0.92 (0.74–1.13)	1.03 (0.95–1.11)	0.305§
p-value¶	0.004	0.046	0.020	-

*Risk in telmisartan/ramipril group.

^¶p-value (telmisartan vs. ramipril) based on non-inferiority margin 1.13.

^†p-value (asians vs. non-asians).

^§p for interaction.